Altimmune, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jerome Benedict Durso
- Full Time Employees
- 57
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 910 Clopper Road Gaithersburg MD United States of America 20878
- IPO Date
- May 26, 2017
- CIK
- 0001326190
- Website
- altimmune.com
- Similar Companies
- Business
- Altimmune, Inc. is a biopharmaceutical company in the late clinical stage, dedicated to developing innovative peptide-based therapies for liver and cardiometabolic conditions. The company's main therapeutic candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing evaluation for several indications, including obesity, metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Regarding pemvidutide's progress, the IMPACT Phase 2b MASH trial has completed enrollment, with 24-week data already published in The Lancet and 48-week data anticipated by the end of 2025. An End-of-Phase 2 meeting with the FDA is scheduled for late 2025, with plans to initiate Phase 3 trials in 2026. Pemvidutide has received Fast Track designation from the U.S. FDA for MASH and AUD. Furthermore, Phase 2 trials for AUD (RECLAIM study) and ALD (RESTORE study) are actively enrolling or have completed enrollment. Previously, Altimmune was developing HepTcell, an immunotherapeutic for chronic hepatitis B. However, the company discontinued its development in March 2024 following Phase 2 trial results that were deemed insufficient to warrant further advancement. The company focuses entirely on advancing pemvidutide through clinical development. Altimmune, Inc. maintains its headquarters in Gaithersburg, Maryland.
Company News
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
Altair Semiconductor Integrates Iridium NTN Direct into ALT1350 and ALT1550 Cellular IoT Chipsets
Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
Altimmune to Participate in Stifel Cardiometabolic Forum
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
Critical Survey: Denali Therapeutics (NASDAQ:DNLI) vs. Altimmune (NASDAQ:ALT)
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
Alpha Liquid Terminal Relaunches as the ALT/X Compute Terminal, Pivoting to GPU Pricing, Power and AI Infrastructure Market Data
Bank of America Corp DE Raises Position in Altimmune, Inc. $ALT
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of “Moderate Buy” from Analysts
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript